ACLX
Arcellx, Inc.
Key Financials
Operating Income
$-253083000
↓ 84.0%
Revenue
$22.3M
↓ 79.4%
Net Income
$-228934000
↓ 113.3%
Total Assets
$604.0M
↓ 15.1%
Total Liabilities
$201.6M
↓ 21.4%
EPS (Diluted)
$-4.07
↓ 103.5%
Shareholders' Equity
$402.4M
↓ 11.5%
Operating Cash Flow
$-210258000.00
↓ 151.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 15-12G | 5/8/2026 | View on SEC |
| SCHEDULE 13D/A | 4/30/2026 | View on SEC |
| 4 | 4/28/2026 | View on SEC |
| 4 | 4/28/2026 | View on SEC |
| 4 | 4/28/2026 | View on SEC |
| 4 | 4/28/2026 | View on SEC |
| 4 | 4/28/2026 | View on SEC |
| 4 | 4/28/2026 | View on SEC |
| 4 | 4/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ACLX |
| Company Name | Arcellx, Inc. |
| CIK | 1786205 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 240-327-0603 |